Working with the institutional review board

Working with an institutional review board (IRB) to ensure compliance and ethical conduct of research involving human subjects is discussed. The Department of Health and Human Services (DHHS) and Food and Drug Administration regulations for the conduct of human research are grounded in the principle...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of health-system pharmacy Vol. 66; no. 2; pp. 176 - 184
Main Author Byerly, Wesley G.
Format Journal Article
LanguageEnglish
Published England American Society of Health-System Pharmacists 15.01.2009
Oxford University Press
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Working with an institutional review board (IRB) to ensure compliance and ethical conduct of research involving human subjects is discussed. The Department of Health and Human Services (DHHS) and Food and Drug Administration regulations for the conduct of human research are grounded in the principles of the Belmont Report. By establishing the requirements for the function and operation of the IRB, the criteria needed for the review and approval of research, and the requirements for obtaining and documenting informed consent, the federal regulations help ensure the safety, rights and welfare of subjects. In developing research protocols and submissions to the IRB, the investigator should include clear, detailed information that addresses the regulatory requirements for the review and approval of research. Before starting a research study, review and approval by the IRB is required unless the study is determined to be minimal risk and fits one of the defined categories. Some research projects involving observation of public behavior, collection of anonymous surveys of nonvulnerable individuals in which the information is not considered sensitive, and evaluation of standard education practices may be exempt from DHHS regulations. Informed consent is central to the protection of human subjects and is required unless the IRB allows a waiver or alteration of informed consent. Once the study is approved, the investigator must conduct the study as approved by the IRB and continue to meet the regulatory requirements related to modifications, reporting unanticipated events, and continuing review. IRB review is integral to ensuring regulatory compliance and ethical conduct of research involving human subjects. Working closely with the IRB or colleagues who have had experience with the IRB will help junior investigators better understand the IRB submission and review process.
AbstractList Working with an institutional review board (IRB) to ensure compliance and ethical conduct of research involving human subjects is discussed. The Department of Health and Human Services (DHHS) and Food and Drug Administration regulations for the conduct of human research are grounded in the principles of the Belmont Report. By establishing the requirements for the function and operation of the IRB, the criteria needed for the review and approval of research, and the requirements for obtaining and documenting informed consent, the federal regulations help ensure the safety, rights and welfare of subjects. In developing research protocols and submissions to the IRB, the investigator should include clear, detailed information that addresses the regulatory requirements for the review and approval of research. Before starting a research study, review and approval by the IRB is required unless the study is determined to be minimal risk and fits one of the defined categories. Some research projects involving observation of public behavior, collection of anonymous surveys of nonvulnerable individuals in which the information is not considered sensitive, and evaluation of standard education practices may be exempt from DHHS regulations. Informed consent is central to the protection of human subjects and is required unless the IRB allows a waiver or alteration of informed consent. Once the study is approved, the investigator must conduct the study as approved by the IRB and continue to meet the regulatory requirements related to modifications, reporting unanticipated events, and continuing review. IRB review is integral to ensuring regulatory compliance and ethical conduct of research involving human subjects. Working closely with the IRB or colleagues who have had experience with the IRB will help junior investigators better understand the IRB submission and review process.
Purpose. Working with an institutional review board (IRB) to ensure compliance and ethical conduct of research involving human subjects is discussed. Summary. The Department of Health and Human Services (DHHS) and Food and Drug Administration regulations for the conduct of human research are grounded in the principles of the Belmont Report. By establishing the requirements for the function and operation of the IRB, the criteria needed for the review and approval of research, and the requirements for obtaining and documenting informed consent, the federal regulations help ensure the safety, rights and welfare of subjects. In developing research protocols and submissions to the IRB, the investigator should include clear, detailed information that addresses the regulatory requirements for the review and approval of research. Before starting a research study, review and approval by the IRB is required unless the study is determined to be minimal risk and fits one of the defined categories. Some research projects involving observation of public behavior, collection of anonymous surveys of nonvulnerable individuals in which the information is not considered sensitive, and evaluation of standard education practices may be exempt from DHHS regulations. Informed consent is central to the protection of human subjects and is required unless the IRB allows a waiver or alteration of informed consent. Once the study is approved, the investigator must conduct the study as approved by the IRB and continue to meet the regulatory requirements related to modifications, reporting unanticipated events, and continuing review. Conclusion. IRB review is integral to ensuring regulatory compliance and ethical conduct of research involving human subjects. Working closely with the IRB or colleagues who have had experience with the IRB will help junior investigators better understand the IRB submission and review process. Index terms: Clinical studies; Compliance; Ethics; Institutional review boards; Methodology Am J Health-Syst Pharm. 2009; 66:176-84
Working with an institutional review board (IRB) to ensure compliance and ethical conduct of research involving human subjects is discussed.PURPOSEWorking with an institutional review board (IRB) to ensure compliance and ethical conduct of research involving human subjects is discussed.The Department of Health and Human Services (DHHS) and Food and Drug Administration regulations for the conduct of human research are grounded in the principles of the Belmont Report. By establishing the requirements for the function and operation of the IRB, the criteria needed for the review and approval of research, and the requirements for obtaining and documenting informed consent, the federal regulations help ensure the safety, rights and welfare of subjects. In developing research protocols and submissions to the IRB, the investigator should include clear, detailed information that addresses the regulatory requirements for the review and approval of research. Before starting a research study, review and approval by the IRB is required unless the study is determined to be minimal risk and fits one of the defined categories. Some research projects involving observation of public behavior, collection of anonymous surveys of nonvulnerable individuals in which the information is not considered sensitive, and evaluation of standard education practices may be exempt from DHHS regulations. Informed consent is central to the protection of human subjects and is required unless the IRB allows a waiver or alteration of informed consent. Once the study is approved, the investigator must conduct the study as approved by the IRB and continue to meet the regulatory requirements related to modifications, reporting unanticipated events, and continuing review.SUMMARYThe Department of Health and Human Services (DHHS) and Food and Drug Administration regulations for the conduct of human research are grounded in the principles of the Belmont Report. By establishing the requirements for the function and operation of the IRB, the criteria needed for the review and approval of research, and the requirements for obtaining and documenting informed consent, the federal regulations help ensure the safety, rights and welfare of subjects. In developing research protocols and submissions to the IRB, the investigator should include clear, detailed information that addresses the regulatory requirements for the review and approval of research. Before starting a research study, review and approval by the IRB is required unless the study is determined to be minimal risk and fits one of the defined categories. Some research projects involving observation of public behavior, collection of anonymous surveys of nonvulnerable individuals in which the information is not considered sensitive, and evaluation of standard education practices may be exempt from DHHS regulations. Informed consent is central to the protection of human subjects and is required unless the IRB allows a waiver or alteration of informed consent. Once the study is approved, the investigator must conduct the study as approved by the IRB and continue to meet the regulatory requirements related to modifications, reporting unanticipated events, and continuing review.IRB review is integral to ensuring regulatory compliance and ethical conduct of research involving human subjects. Working closely with the IRB or colleagues who have had experience with the IRB will help junior investigators better understand the IRB submission and review process.CONCLUSIONIRB review is integral to ensuring regulatory compliance and ethical conduct of research involving human subjects. Working closely with the IRB or colleagues who have had experience with the IRB will help junior investigators better understand the IRB submission and review process.
Audience Academic
Author Wesley G. Byerly
Author_xml – sequence: 1
  givenname: Wesley G.
  surname: Byerly
  fullname: Byerly, Wesley G.
  organization: Duke University School of Medicine, Durham, NC 27708
BackLink https://www.ncbi.nlm.nih.gov/pubmed/19139484$$D View this record in MEDLINE/PubMed
BookMark eNptkEtLJDEURoMo43PjDxhq4yxGSm8encdSZEYFwY3iMqSqbnXFqUebpC389xNpR0GGLBLC-T7uPftke5xGJOSYwhmjQp67p24FCkDKLbJHF3xRMgOwnd-gTMlAs12yH-MTAGUa5DeySw3lRmixR04fp_DHj8ti9qkrUoeFH2PyaZ38NLq-CPjicS6qyYXmkOy0ro949H4fkIffv-4vr8vbu6uby4vbsuYLkUoFLTONVOgcY21lJErNK6mE05xRtaiMUJqDqQANRaq5roVqRGNaQx1nwA_Ij03vKkzPa4zJDj7W2PduxGkdrZSa5g1EBs824NL1aP3YTim4Op8GB19nSa3P_xcs702ZkjIHvr83r6sBG7sKfnDh1f7zkQHYAHWYYgzY2ton9-YiN_veUrBvyu2n8hz5-SXy0fo_-GQDd37ZzT6gjYPr-zwOs_M8S2mZpUryvwrGjEw
CitedBy_id crossref_primary_10_1177_1556264616631657
crossref_primary_10_3233_BMR_210153
crossref_primary_10_1080_08989621_2014_956866
crossref_primary_10_1007_s10877_014_9582_6
crossref_primary_10_1177_15562646211009680
crossref_primary_10_3928_00220124_20111101_03
crossref_primary_10_1016_j_outlook_2010_04_003
crossref_primary_10_1016_j_dental_2011_08_595
crossref_primary_10_1213_ANE_0b013e3181cc5727
crossref_primary_10_3390_s23115003
crossref_primary_10_5435_00124635_201306000_00006
crossref_primary_10_2146_ajhp120449
crossref_primary_10_2146_ajhp170183
crossref_primary_10_3999_jscpt_41_113
crossref_primary_10_1002_eahr_500202
crossref_primary_10_2146_ajhp120167
crossref_primary_10_3346_jkms_2023_38_e198
crossref_primary_10_1007_s40617_018_0206_3
crossref_primary_10_1097_NUR_0000000000000197
crossref_primary_10_1017_S1461145710001112
crossref_primary_10_3390_f13101625
crossref_primary_10_1002_wjs_12038
crossref_primary_10_1007_s40615_023_01800_5
crossref_primary_10_3928_00220124_20111101_64
crossref_primary_10_1002_aorn_13498
crossref_primary_10_1093_bja_aes298
crossref_primary_10_1310_hpj5202_105
Cites_doi 10.1097/00019514-200610000-00003
10.1056/NEJM198707163170304
10.1016/j.jclinepi.2005.11.018
10.1001/jama.1996.03540200077043
10.1177/0894318405277534
10.1001/jama.283.17.2275
10.1378/chest.130.5.1605
ContentType Journal Article
Copyright COPYRIGHT 2009 Oxford University Press
Copyright_xml – notice: COPYRIGHT 2009 Oxford University Press
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.2146/ajhp070066
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Public Health
Pharmacy, Therapeutics, & Pharmacology
EISSN 1535-2900
EndPage 184
ExternalDocumentID A201212766
19139484
10_2146_ajhp070066
www66_2_176
Genre Journal Article
Review
GeographicLocations United States
GeographicLocations_xml – name: United States
GroupedDBID -
04C
0R
23M
4.4
48X
53G
5GY
5RE
5RS
5WD
AABJS
AABMN
AAIMJ
AALRV
AAPBV
AAPQZ
AAWTL
AAYEP
ABDBF
ABFLS
ABPTK
ACDCL
ACIMA
ACIWK
ACPRK
ADBBV
ADEIU
ADGZP
ADIPN
ADRTK
AELNO
AELWJ
AENEX
AETBJ
AFRAH
AGINJ
AGVJH
AIKOY
AIMBJ
ALMA_UNASSIGNED_HOLDINGS
BCRHZ
BEYMZ
CS3
EAD
EAP
EAS
EBC
EBD
EBS
ECF
ECT
ECV
EHN
EJD
EMB
EMK
ENC
ENERS
EPL
EPT
EST
ESX
EX3
F5P
FH7
FHSFR
FOTVD
FQBLK
GAUVT
H13
IAO
IHR
INH
INR
ITC
J5H
KBUDW
KOP
KSN
L7B
M5
MHKGH
MV1
NLBLG
NOYVH
NVLIB
O9-
OB4
OBOKY
OCZFY
ODMLO
OVD
OWPYF
P2P
Q~Q
R0Z
RHI
ROX
RZL
SJN
SV3
TSH
TUS
WH7
WOW
XZ
YCJ
YXANX
---
.XZ
08P
0R~
1CY
36B
6J9
6PF
AABZA
AACZT
AAPXW
AARHZ
AAUAY
AAVAP
AAYOK
AAYXX
ABCQX
ABDFA
ABEJV
ABGNP
ABJNI
ABMNT
ABNHQ
ABPQP
ABPTD
ABQNK
ABVGC
ABWST
ABXVV
ABXZS
ACFRR
ACGFO
ACUHS
ACUTJ
ACYHN
ADGKP
ADNBA
ADOJX
ADQBN
ADVEK
AEGXH
AEMQT
AFFZL
AFGWE
AFXAL
AGORE
AGQXC
AGUTN
AHMMS
AIAGR
AJEEA
AJNCP
ALXQX
ATGXG
BMSDO
C45
CITATION
EIHBH
EMOBN
FECEO
FLUFQ
FOEOM
JXSIZ
KSI
M5~
MK0
NOMLY
OAUYM
OFXIZ
OJZSN
OPAEJ
OVIDX
PONUX
RUSNO
TEORI
TMA
VVN
WQ9
YFH
YOC
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c354t-70f29d67eaa22fb96e683b674a832175b9478309b0e91e1838c47d4d9f91a3203
ISSN 1079-2082
1535-2900
IngestDate Tue Aug 05 09:46:43 EDT 2025
Tue Jun 10 21:24:19 EDT 2025
Wed Feb 19 02:33:40 EST 2025
Tue Jul 01 02:55:54 EDT 2025
Thu Apr 24 22:58:21 EDT 2025
Tue Jan 05 20:16:59 EST 2021
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c354t-70f29d67eaa22fb96e683b674a832175b9478309b0e91e1838c47d4d9f91a3203
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
PMID 19139484
PQID 66811914
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_66811914
gale_infotracacademiconefile_A201212766
pubmed_primary_19139484
crossref_citationtrail_10_2146_ajhp070066
crossref_primary_10_2146_ajhp070066
highwire_smallpub2_www66_2_176
ProviderPackageCode RHI
CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20090115
2009-01-15
2009-Jan-15
PublicationDateYYYYMMDD 2009-01-15
PublicationDate_xml – month: 01
  year: 2009
  text: 20090115
  day: 15
PublicationDecade 2000
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle American journal of health-system pharmacy
PublicationTitleAlternate Am J Health Syst Pharm
PublicationYear 2009
Publisher American Society of Health-System Pharmacists
Oxford University Press
Publisher_xml – name: American Society of Health-System Pharmacists
– name: Oxford University Press
References ( key 2019041002323634100_R1) 1996; 276
( key 2019041002323634100_R13) 2000; 283
( key 2019041002323634100_R14) 2001; 36
( key 2019041002323634100_R11) 2006
( key 2019041002323634100_R18) 1987; 317
( key 2019041002323634100_R21) 2007
( key 2019041002323634100_R17) 2005; 18
( key 2019041002323634100_R24) 2007
( key 2019041002323634100_R4) 2007
( key 2019041002323634100_R5) 1986
( key 2019041002323634100_R15) 2006; 15
( key 2019041002323634100_R9) 2006
( key 2019041002323634100_R12) 2007
( key 2019041002323634100_R22) 2007
( key 2019041002323634100_R16) 2006; 130
( key 2019041002323634100_R6) 1982
( key 2019041002323634100_R7) 2007
( key 2019041002323634100_R2) 2007
( key 2019041002323634100_R3) 2007
( key 2019041002323634100_R25) 2007
( key 2019041002323634100_R8) 2007
( key 2019041002323634100_R20) 2007
( key 2019041002323634100_R23) 2007
( key 2019041002323634100_R10) 2006
( key 2019041002323634100_R19) 2006; 59
References_xml – year: 2006
  ident: key 2019041002323634100_R10
– year: 2007
  ident: key 2019041002323634100_R4
– volume: 15
  start-page: 215
  year: 2006
  ident: key 2019041002323634100_R15
  publication-title: Qual Manag Health Care
  doi: 10.1097/00019514-200610000-00003
– year: 2007
  ident: key 2019041002323634100_R21
– year: 2007
  ident: key 2019041002323634100_R25
– year: 1982
  ident: key 2019041002323634100_R6
– year: 2007
  ident: key 2019041002323634100_R12
– volume: 317
  start-page: 141
  year: 1987
  ident: key 2019041002323634100_R18
  publication-title: N Engl J Med
  doi: 10.1056/NEJM198707163170304
– year: 2007
  ident: key 2019041002323634100_R20
– volume: 59
  start-page: 784
  year: 2006
  ident: key 2019041002323634100_R19
  publication-title: J Clin Epidemiol
  doi: 10.1016/j.jclinepi.2005.11.018
– year: 2007
  ident: key 2019041002323634100_R22
– year: 2006
  ident: key 2019041002323634100_R11
– year: 2007
  ident: key 2019041002323634100_R8
– year: 2006
  ident: key 2019041002323634100_R9
– year: 1986
  ident: key 2019041002323634100_R5
– year: 2007
  ident: key 2019041002323634100_R23
– year: 2007
  ident: key 2019041002323634100_R7
– volume: 276
  start-page: 1691
  year: 1996
  ident: key 2019041002323634100_R1
  publication-title: JAMA
  doi: 10.1001/jama.1996.03540200077043
– volume: 36
  start-page: 213
  year: 2001
  ident: key 2019041002323634100_R14
  publication-title: Formulary
– volume: 18
  start-page: 264
  year: 2005
  ident: key 2019041002323634100_R17
  publication-title: Nurs Sci Q
  doi: 10.1177/0894318405277534
– year: 2007
  ident: key 2019041002323634100_R3
– volume: 283
  start-page: 2275
  year: 2000
  ident: key 2019041002323634100_R13
  publication-title: JAMA
  doi: 10.1001/jama.283.17.2275
– volume: 130
  start-page: 1605
  year: 2006
  ident: key 2019041002323634100_R16
  publication-title: Chest
  doi: 10.1378/chest.130.5.1605
– year: 2007
  ident: key 2019041002323634100_R24
– year: 2007
  ident: key 2019041002323634100_R2
SSID ssj0012806
Score 2.030588
SecondaryResourceType review_article
Snippet Working with an institutional review board (IRB) to ensure compliance and ethical conduct of research involving human subjects is discussed. The Department of...
Purpose. Working with an institutional review board (IRB) to ensure compliance and ethical conduct of research involving human subjects is discussed. Summary....
Working with an institutional review board (IRB) to ensure compliance and ethical conduct of research involving human subjects is discussed.PURPOSEWorking with...
SourceID proquest
gale
pubmed
crossref
highwire
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 176
SubjectTerms Biomedical Research - ethics
Biomedical Research - standards
Ethics Committees, Research - ethics
Ethics Committees, Research - standards
Human Experimentation - ethics
Human Experimentation - standards
Human experimentation in medicine
Humans
Self-experimentation in medicine
United States
United States Dept. of Health and Human Services - ethics
United States Dept. of Health and Human Services - standards
Title Working with the institutional review board
URI http://www.ajhp.org/content/66/2/176.abstract
https://www.ncbi.nlm.nih.gov/pubmed/19139484
https://www.proquest.com/docview/66811914
Volume 66
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZb-jIYY-tu2aUTbHSMVMGWFdl6TLZ1ZQ-jDyn0TUi2TBlpEpaUkP36HfnIl4SOXV5MMEKW9Z0c69y-Q8i72MZlZEzE4kRaBvaGYaYUCZOFzVyRCCdslW3xTZ5diK-Xo8s2ib2qLlnbYf7z1rqS_0EV7gGuvkr2H5BtJoUb8BvwhSsgDNe_wjh4uoMz9crzf2DoH_17oSzFLkLlfMM2W0dpOrQRWA_JkNh5sERC69bd7rxve_BlOJhsmwzQ2lfgM6EYVkt20vO93ggZoT5WgNMjP_rgHKcHCeu4CsFCVLDv2CRo6GpFOWJcRVFXk2L_lCAxvKMWY-zxsq-ueeAp_n61BM0TyZ1BsNXL6wq42FOXIuXpHmP23pesyS_cbDZSaq7huXfJAQcLgvfIwXjyaXLahJh8SBkTUvHlkLuWVx2AmgVVnLL49J2DS_35rjmlf2-fVOeU6UPyIBgYdIzS8ojccfNDchx2fHtCp23B3eqEHtPzlrt8e0juoxuXIl6PSR1MoV7EKIgY3RExiiJGKxF7Qi5OP08_nrHQX4PlyUisWRqVXBUydcZwXlolncwSK1NhfPuqdGSVSLMkUjZyKnag-7NcpIUoVKlik_AoeUp688XcPSc0t0WRypKX0uZCOaFEXsIMoiyKgqtc9cmHevN0HsjnfQ-UmQYjlFeF8c2e98nbZuwSKVduHfXeY6C9qMBMuQnlJLAez2imx9yzFfLUjzyqYdKrazObATxcd0SkT97U4GlQrj5iZuZucbPSUmYVAWKfPENM2wUFqXjxp8lfknvtP_EV6a1_3LjXcI5d26Mgkb8Aetifjw
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Working+with+the+institutional+review+board&rft.jtitle=American+journal+of+health-system+pharmacy&rft.au=Wesley+G.+Byerly&rft.date=2009-01-15&rft.pub=American+Society+of+Health-System+Pharmacists&rft.issn=1079-2082&rft.eissn=1535-2900&rft.volume=66&rft.issue=2&rft.spage=176&rft_id=info:doi/10.2146%2Fajhp070066&rft_id=info%3Apmid%2F19139484&rft.externalDBID=n%2Fa&rft.externalDocID=www66_2_176
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1079-2082&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1079-2082&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1079-2082&client=summon